Chile's CFR Pharmaceuticals is threatening to pull its $1.3 billion bid for South African drugmaker Adcock Ingram if the latter's biggest shareholder doesn't come on board with the deal. But CFR chief Alejandro Weinstein is in Johannesburg this week hoping to salvage the deal.
Floundering Transcept Pharmaceuticals is cutting 43% of its workforce and shuffling its board, looking to cut costs as it scouts for a buyer.
Will Endo Health Solutions follow in Valeant Pharmaceuticals' footsteps? Already the U.S.-based company has taken one page from Valeant CEO Michael Pearson's playbook, with last week's tax-friendly buyout of Paladin Labs. Can a Valeant-esque series of buyouts be on its way?
Troubled Dendreon is again cutting its payroll, planning to shed about 200 employees in an effort to water down its cash burn rate and finally turn a profit. But, with a disappointing prostate cancer drug and a dim outlook for the future, the Seattle drugmaker may need more than lighter books to reverse its fortunes or find an acquirer.
Solta Medical, a maker of medical devices focused on liposuction, skin resurfacing and other aesthetic areas, will reorganize, slash jobs and may even sell itself in a bid to reverse slumping sales.
Shire is one of those companies that's always rumored to be a buyer or a seller. Not so long ago, it was setting up poison-pill protections against an unwanted suitor. Now, it has beat out Big Pharma with a deal for ViroPharma, the maker of rare disease drugs.
The Novartis sales have officially begun. The Swiss drugmaker has now agreed to sell its blood diagnostics business to Grifols, the Spanish healthcare company, for $1.7 billion. As analysts digest the news, they're already asking which unit will be next to go.
Quintiles declined to divulge financials when it signed up to buy Novella Clinical in August, but a regulatory filing reveals that the world's largest CRO spent $146.5 million upfront for the contractor, with more money on the line tied to milestones.
The buyout--at $50 a share--will add Cinryze for hereditary angioedema to Shire's product lineup along with the experimental drug maribavir for cytomegalovirus, one of 8 clinical-stage programs in the pipeline.
Salix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout.